ME3BP-7 is a targeted cytotoxic agent that rapidly kills pancreatic cancer cells expressing high levels of monocarboxylate transporter MCT1 (Updated July 29, 2024).

A preprint abstract from biorxiv.org discusses a potential new treatment for pancreatic cancer. The study focuses on a targeted cytotoxic agent called ME3BP-7, which is effective against pancreatic cancer cells that overexpress the Monocarboxylate Transporter 1 (MCT1). Previous attempts to inhibit MCT1 with biochemical inhibitors have been unsuccessful in clinical trials. However, the researchers describe a microencapsulated formulation of ME3BP-7 that shows promise in reducing pancreatic cancer growth and metastasis in multiple models. This research has not yet undergone peer review. [Extracted from the article]